Relay Therapeutics (RLAY) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to -$74.0 million.
- Relay Therapeutics' Income towards Parent Company rose 16.02% to -$74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.8 million, marking a year-over-year increase of 14.03%. This contributed to the annual value of -$337.7 million for FY2024, which is 1.24% up from last year.
- Latest data reveals that Relay Therapeutics reported Income towards Parent Company of -$74.0 million as of Q3 2025, which was down 6.08% from -$69.7 million recorded in Q2 2025.
- In the past 5 years, Relay Therapeutics' Income towards Parent Company registered a high of -$42.2 million during Q1 2021, and its lowest value of -$193.4 million during Q2 2021.
- Its 3-year average for Income towards Parent Company is -$81.9 million, with a median of -$81.4 million in 2024.
- Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 677.14% in 2021, then spiked by 60.29% in 2022.
- Relay Therapeutics' Income towards Parent Company (Quarterly) stood at -$67.5 million in 2021, then decreased by 0.03% to -$67.5 million in 2022, then declined by 23.74% to -$83.5 million in 2023, then increased by 8.97% to -$76.0 million in 2024, then increased by 16.02% to -$74.0 million in 2025.
- Its Income towards Parent Company stands at -$74.0 million for Q3 2025, versus -$69.7 million for Q2 2025 and -$77.1 million for Q1 2025.